Skip to main content

Bolt Biotherapeutics, Inc. (BOLT)

NASDAQ: BOLT · IEX Real-Time Price · USD
13.96 -1.33 (-8.70%)
Sep 20, 2021 4:00 PM EDT - Market closed
Market Cap520.82M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out36.60M
EPS (ttm)-5.71
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume268,826
Open15.22
Previous Close15.29
Day's Range13.53 - 15.22
52-Week Range10.75 - 43.07
Betan/a
Analystsn/a
Price Target39.75 (+184.7%)
Est. Earnings DateNov 11, 2021

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to im...

IndustryBiotechnology
IPO DateFeb 5, 2021
Employees65
Stock ExchangeNASDAQ
Ticker SymbolBOLT
Full Company Profile

Financial Performance

In 2020, BOLT's revenue was $231,000, an increase of 7.44% compared to the previous year's $215,000. Losses were -$60.73 million, 99.2% more than in 2019.

Financial Statements

News

Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with...

REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine t...

1 week ago - GlobeNewsWire

Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences

REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the tar...

2 weeks ago - GlobeNewsWire

Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

SAN FRANCISCO and SUZHOU, China, Aug. 26, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

3 weeks ago - PRNewsWire

Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

REDWOOD CITY, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine th...

3 weeks ago - GlobeNewsWire

Hot Small-Cap Stocks To Watch With Potential Cancer Breakthroughs

Could new cancer treatment breakthroughs be a bullish sign for small cap stocks?

Other symbols:BEAMGMABMGNXZLAB
2 months ago - PennyStocks

Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001...

REDWOOD CITY, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine th...

3 months ago - GlobeNewsWire

Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properti...

Bolt's first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC) currently in an ongoing Phase 1/2 first-in-human study Bolt's first-in...

5 months ago - GlobeNewsWire

Bolt Biotherapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

REDWOOD CITY, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the tar...

5 months ago - GlobeNewsWire

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

– Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a total of $358 million in recent fundraising –

5 months ago - GlobeNewsWire

5 Recent Red-Hot IPOs Are Being Added to the Russell 2000 Next Week

Last year was a monster year for the initial public offering market, and 2021 looks like it could provide a repeat performance.

Other symbols:MASSMDWTNEXIOCDX
6 months ago - 24/7 Wall Street

Bolt Biotherapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Pu...

REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the closing of its initial public offering of...

7 months ago - GlobeNewsWire

Bolt Biotherapeutics Prices Upsized Initial Public Offering

REDWOOD CITY, Calif.-- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced...

7 months ago - GlobeNewswire

Solid tumor biotech Bolt Biotherapeutics files for a $100 million IPO

Bolt Biotherapeutics, a Phase 1/2 biotech developing targeted therapies for solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

8 months ago - NASDAQ

Bolt Biotherapeutics IPO Registration Document (S-1)

Bolt Biotherapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

8 months ago - SEC